These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 25858463)

  • 1. Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?
    Yeomans ND
    BMC Med; 2015 Mar; 13():56. PubMed ID: 25858463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks.
    Scarpignato C; Lanas A; Blandizzi C; Lems WF; Hermann M; Hunt RH;
    BMC Med; 2015 Mar; 13():55. PubMed ID: 25857826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NSAID dilemma: managing osteoarthritis in high-risk patients.
    Roth SH; Anderson S
    Phys Sportsmed; 2011 Sep; 39(3):62-74. PubMed ID: 22030942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
    Borer JS; Simon LS
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.
    Scheiman JM; Fendrick AM
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S23-9. PubMed ID: 16168078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ; Benraad HB; Rasker JJ
    Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoarthritis therapy--are there still unmet needs?
    Laufer S
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nonsteroidal anti-inflammatory agents--choice between disturbances of gastrointestinal tract and cardiovascular toxicity].
    Gumbrevicius G; Milasius A; Sveikata A
    Medicina (Kaunas); 2006; 42(5):429-39. PubMed ID: 16778472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular and gastrointestinal safety of NSAIDs].
    van den Bemt P; Tjwa ET; van Oijen MG
    Ned Tijdschr Geneeskd; 2014; 158():A7311. PubMed ID: 24713339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
    Hermann M
    Praxis (Bern 1994); 2012 Oct; 101(20):1309-14. PubMed ID: 23032496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.
    Davies NM; Reynolds JK; Undeberg MR; Gates BJ; Ohgami Y; Vega-Villa KR
    Expert Rev Neurother; 2006 Nov; 6(11):1643-55. PubMed ID: 17144779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the adverse effects of nonsteroidal anti-inflammatory drugs.
    Patrignani P; Tacconelli S; Bruno A; Sostres C; Lanas A
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):605-21. PubMed ID: 22114888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases.
    Scheiman JM
    Drugs; 2006; 66 Suppl 1():15-21; discussion 29-33. PubMed ID: 16869344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A choice of a nonsteroidal anti-inflammatory drug with regard to gastrointestinal and cardiovascular' risks].
    Pakhomova IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(4):85-89. PubMed ID: 27386591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.